Data, patients and payers key to “New Health” success, says Quintiles

By Gareth Macdonald

- Last updated on GMT

Related tags: Pharmacology

Data, patients and payers key to “New Health” success, says Quintiles
Quintiles’ Jay Norman tells Outsourcing-pharma that data sharing and patient and payer concerns will drive drug industry competition and clinical development decisions accord to new research.

The contract research organisation (CRO) completed its “New Health” report analysing the drug development industry’s evolution during what Norman described as a “period of constant change.​”

He predicted that the tough pharmaceutical market is going to get tougher as industry adapts to managing relationships with new “constellation” of patient, payer and policy making stakeholders.

Norman also revealed that the focus of drug industry competition seems to be shifting away from capital expenditure and science to data and analytics, particularly when companies are deciding which drugs to take into clinical development and when.

We expect to see increased information exchange between pharma competitors and payers…to share data around why products fail and what seems to be working​,” he explained, adding that while pharma focuses on trials and getting to market, patients and payers are look at quality of life benefits post market.

Related news

Show more

Related products

show more

GLP Tissue Cross Reactivity Testing

GLP Tissue Cross Reactivity Testing

Precision for Medicine | 11-Oct-2021 | Product Brochure

Precision for Medicine's unique combination of research services and tissue procurement capabilities form the pillars of our GLP Tissue Cross Reactivity...

Automating clinical trials for success

Automating clinical trials for success

Formedix | 06-Oct-2021 | Technical / White Paper

This article gives gives a brief overview of why automation is absolutely essential for clinical trial success.

Related suppliers

Follow us


View more